Skip to main content
Caplight Logo









Allotera Therapeutics

Allotera Therapeutics

Private
St. Louis, MissouriHealthcare & Life Scienceshttps://alloteratx.com/

Last Round

Series C

Extension

Jul 8, 2026

Total Funding Raised

$394M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Allotera Therapeutics is a biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for the treatment of hematological malignancies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapyallogeneic cell therapyoff-the-shelf therapybiotechnologyhematologic malignanciescell therapychemistry, manufacturing, and controlsCMCacute myeloid leukemiaAMLT-cell cancernext-gen immunotherapyclinical-stage biotechbiologics R&Doff-the-shelf CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allotera Therapeutics Comparables

Compare Allotera Therapeutics with similar companies based on industry and business-model similarity.

Allotera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bioheng Therapeutics
89%
Beam Therapeutics
83%
AvenCell
81%

Allotera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionJul 8, 2026
Series CAug 27, 2025
Series BJul 15, 2021
Series AApr 13, 2020

Key People

Founding team and executive leadership

Kumar Srinivasan

Chief Executive Officer

Executive Team

Jim Faulkner

Chief Technology Officer

Executive Team

Allotera Therapeutics Investors

Notable investors and investment history

Allotera Therapeutics investors
InvestorRounds
LYZZ CapitalSeries B, Series C, Series A
Intermediate Capital GroupSeries C, Series B
Fidelity Management & Research CompanySeries B, Series C
BioGenerator VenturesSeries C Extension, Series A
Tybourne Capital ManagementSeries C, Series B
RiverVest Venture PartnersSeries B, Series C, Series A
AbingworthSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 8, 2026

    $35M round with participation from BioGenerator Ventures and LightChain Capital.

  • Aug 27, 2025

    $115M raised in early funding.

Allotera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allotera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allotera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSt. Louis, Missouri
Employee Range44
Year Founded2018
Last FundingJul 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?